Cargando…
The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial
BACKGROUND: Septic shock is common and has unacceptably high morbidity, mortality, and associated cost with numerous failed attempts at developing effective therapies. Endotoxin, one of the most potent mediators of sepsis, is found in high levels in approximately 50% of patients with septic shock. P...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066268/ https://www.ncbi.nlm.nih.gov/pubmed/24916483 http://dx.doi.org/10.1186/1745-6215-15-218 |
_version_ | 1782322157928316928 |
---|---|
author | Klein, David J Foster, Debra Schorr, Christa A Kazempour, Kazem Walker, Paul M Dellinger, R Phillip |
author_facet | Klein, David J Foster, Debra Schorr, Christa A Kazempour, Kazem Walker, Paul M Dellinger, R Phillip |
author_sort | Klein, David J |
collection | PubMed |
description | BACKGROUND: Septic shock is common and has unacceptably high morbidity, mortality, and associated cost with numerous failed attempts at developing effective therapies. Endotoxin, one of the most potent mediators of sepsis, is found in high levels in approximately 50% of patients with septic shock. Polymyxin B (PMX) hemoperfusion has been shown in numerous studies to successfully remove endotoxin and potentially improve outcomes. EUPHRATES (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock) is a theragnostic trial (matching blood measurement to treatment capability) of PMX hemoperfusion in patients with septic shock and confirmed endotoxemia as measured by the endotoxin activity assay (EAA). METHODS: EUPHRATES is a pivotal regulatory trial that is multi-centered, placebo-controlled and blinded. The trial is being conducted in fifty ICUs in the United States and Canada and is powered to enroll 360 patients. Patients with persistent septic shock despite adequate fluid resuscitation on vasopressors for more than 2 and less than 30 hours are eligible for measurement of the EAA. Those with EAA ≥0.60 are eligible to be randomized to treatment with two sessions of PMX hemoperfusion 24 hours apart. The primary endpoint for the trial is 28-day all-cause mortality. DISCUSSION: Unique features of the trial include absence of systemic inflammatory response (SIRS) criteria as a requirement for inclusion, use of the EAA to confirm endotoxemia as a requisite for treatment, and use of a detailed “façade” hemoperfusion event as a blinding mechanism. The outcomes of the second interim analysis included a resizing of the trial to 650 patients and the addition of an exclusion criterion of subjects with multiple organ dysfunction score (MODS) ≤ 9. Results are anticipated in 2016. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01046669. Registered: January 8, 2010. |
format | Online Article Text |
id | pubmed-4066268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40662682014-06-24 The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial Klein, David J Foster, Debra Schorr, Christa A Kazempour, Kazem Walker, Paul M Dellinger, R Phillip Trials Study Protocol BACKGROUND: Septic shock is common and has unacceptably high morbidity, mortality, and associated cost with numerous failed attempts at developing effective therapies. Endotoxin, one of the most potent mediators of sepsis, is found in high levels in approximately 50% of patients with septic shock. Polymyxin B (PMX) hemoperfusion has been shown in numerous studies to successfully remove endotoxin and potentially improve outcomes. EUPHRATES (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock) is a theragnostic trial (matching blood measurement to treatment capability) of PMX hemoperfusion in patients with septic shock and confirmed endotoxemia as measured by the endotoxin activity assay (EAA). METHODS: EUPHRATES is a pivotal regulatory trial that is multi-centered, placebo-controlled and blinded. The trial is being conducted in fifty ICUs in the United States and Canada and is powered to enroll 360 patients. Patients with persistent septic shock despite adequate fluid resuscitation on vasopressors for more than 2 and less than 30 hours are eligible for measurement of the EAA. Those with EAA ≥0.60 are eligible to be randomized to treatment with two sessions of PMX hemoperfusion 24 hours apart. The primary endpoint for the trial is 28-day all-cause mortality. DISCUSSION: Unique features of the trial include absence of systemic inflammatory response (SIRS) criteria as a requirement for inclusion, use of the EAA to confirm endotoxemia as a requisite for treatment, and use of a detailed “façade” hemoperfusion event as a blinding mechanism. The outcomes of the second interim analysis included a resizing of the trial to 650 patients and the addition of an exclusion criterion of subjects with multiple organ dysfunction score (MODS) ≤ 9. Results are anticipated in 2016. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01046669. Registered: January 8, 2010. BioMed Central 2014-06-11 /pmc/articles/PMC4066268/ /pubmed/24916483 http://dx.doi.org/10.1186/1745-6215-15-218 Text en Copyright © 2014 Klein et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Klein, David J Foster, Debra Schorr, Christa A Kazempour, Kazem Walker, Paul M Dellinger, R Phillip The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial |
title | The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial |
title_full | The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial |
title_fullStr | The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial |
title_full_unstemmed | The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial |
title_short | The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial |
title_sort | euphrates trial (evaluating the use of polymyxin b hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock): study protocol for a randomized controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066268/ https://www.ncbi.nlm.nih.gov/pubmed/24916483 http://dx.doi.org/10.1186/1745-6215-15-218 |
work_keys_str_mv | AT kleindavidj theeuphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT fosterdebra theeuphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT schorrchristaa theeuphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT kazempourkazem theeuphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT walkerpaulm theeuphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT dellingerrphillip theeuphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT kleindavidj euphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT fosterdebra euphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT schorrchristaa euphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT kazempourkazem euphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT walkerpaulm euphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial AT dellingerrphillip euphratestrialevaluatingtheuseofpolymyxinbhemoperfusioninarandomizedcontrolledtrialofadultstreatedforendotoxemiaandsepticshockstudyprotocolforarandomizedcontrolledtrial |